Bevacizumab versus Dexamethasone Implant Followed by Bevacizumab for the Treatment of Macula Edema Associated with Branch Retinal Vein Occlusion

Purpose To compare visual and anatomical outcomes of intravitreal injections of bevacizumab and dexamethasone implant (Ozurdex) treatment for macular edema associated with branch retinal vein occlusion (BRVO). Methods We retrospectively reviewed patients who underwent intravitreal bevacizumab administered monthly on a pro re nata (PRN) basis (26 eyes, IVB group) or an initial 700-µg dexamethasone implant followed by a bevacizumab PRN injection (20 eyes, IVD group) for treatment of macular edema associated with BRVO. We compared best-corrected visual acuity (BCVA) and central macular thickness (CMT). We also measured ellipsoid zone recovery rate and ganglion cell-inner plexiform layer volume within the center 6 mm zone. A linear mixed model analysis was performed to compare serial changes in BCVA and CMT. Results Both groups showed significant improvement in BCVA and significant reduction in CMT. However, BCVA in the first month was significantly better in the IVD group (logarithm of the minimum angle of resolution, IVD group 0.21 ± 0.26 vs. IVB group 0.39 ± 0.30, p = 0.038) and the 1-month CMT was thinner in the IVD group (IVD group 270.0 ± 62.0 µm vs. IVB group 338.9 ± 122.6 µm, p = 0.028), and these trends were maintained during the 6-month follow-up. The IVD group showed more rapid macular edema resolution (p = 0.049); however, there were no significant differences in ellipsoid zone recovery rate (p = 0.268) or ganglion cell-inner plexiform layer volume between the two groups (p = 0.459). Conclusions There were no significant differences in final visual or anatomical outcomes between the two groups; however, initial dexamethasone implant injection followed by bevacizumab PRN injection initially showed more rapid improvement in vision and BRVO-associated macular edema resolution compared to intravitreal bevacizumab administered monthly on a PRN basis.

[1]  N. Eter,et al.  Clinical Efficacy and Safety of Ranibizumab Versus Dexamethasone for Central Retinal Vein Occlusion (COMRADE C): A European Label Study. , 2016, American journal of ophthalmology.

[2]  Y. Mitamura,et al.  Optical coherence tomography parameters predictive of visual outcome after anti-VEGF therapy for retinal vein occlusion , 2016, Clinical ophthalmology.

[3]  J. Garweg,et al.  Retinal vein occlusion and the use of a dexamethasone intravitreal implant (Ozurdex®) in its treatment , 2016, Graefe's Archive for Clinical and Experimental Ophthalmology.

[4]  J. Chhablani,et al.  In vivo evaluation of retinal ganglion cells degeneration in eyes with branch retinal vein occlusion , 2016, British Journal of Ophthalmology.

[5]  P. Campochiaro,et al.  Intravitreal Aflibercept for Macular Edema Following Branch Retinal Vein Occlusion: 52-Week Results of the VIBRANT Study. , 2016, Ophthalmology.

[6]  H. Lim,et al.  Prediction of Retinal Ischemia in Branch Retinal Vein Occlusion: Spectral-Domain Optical Coherence Tomography Study. , 2015, Investigative ophthalmology & visual science.

[7]  Ahmed S. Gado,et al.  Dexamethasone intravitreous implant versus bevacizumab for central retinal vein occlusion‐related macular oedema: a prospective randomized comparison , 2014, Clinical & experimental ophthalmology.

[8]  Min Kim,et al.  Comparison of intravitreal bevacizumab and dexamethasone implant for the treatment of macula oedema associated with branch retinal vein occlusion , 2015, British Journal of Ophthalmology.

[9]  P. Campochiaro,et al.  Intravitreal aflibercept for macular edema following branch retinal vein occlusion: the 24-week results of the VIBRANT study. , 2015, Ophthalmology.

[10]  C. Chiquet,et al.  Intravitreal dexamethasone implant versus anti-VEGF injection for treatment-naïve patients with retinal vein occlusion and macular edema: a 12-month follow-up study , 2015, Graefe's Archive for Clinical and Experimental Ophthalmology.

[11]  Jae Hui Kim,et al.  Short-term efficacy of intravitreal triamcinolone acetonide for macular edema secondary to retinal vein occlusion that is refractory to intravitreal bevacizumab , 2015, Indian journal of ophthalmology.

[12]  Yong-Kyu Kim,et al.  Comparison of visual and anatomical outcomes of half-fluence and half-dose photodynamic therapy in eyes with chronic central serous chorioretinopathy , 2015, Graefe's Archive for Clinical and Experimental Ophthalmology.

[13]  M. Gillies,et al.  A randomized clinical trial of intravitreal bevacizumab versus intravitreal dexamethasone for diabetic macular edema: the BEVORDEX study. , 2014, Ophthalmology.

[14]  G. Pertile,et al.  Intravitreal Dexamethasone Implant for Macular Edema Secondary to Retinal Vein Occlusion: 12-month Follow-Up and Prognostic Factors , 2014, Ophthalmologica.

[15]  Ahmed S. Gado,et al.  Dexamethasone intravitreous implant versus bevacizumab for central retinal vein occlusion‐related macular oedema: a prospective randomized comparison , 2014, Clinical & experimental ophthalmology.

[16]  D. Gaucher,et al.  Prospective Pilot Study: Efficacy of Intravitreal Dexamethasone and Bevacizumab Injections in the Treatment of Macular Oedema Associated with Branch Retinal Vein Occlusion , 2013, Ophthalmologica.

[17]  M. Blumenkranz,et al.  Dexamethasone intravitreal implant in patients with macular edema related to branch or central retinal vein occlusion twelve-month study results. , 2011, Ophthalmology.

[18]  M. Figueroa,et al.  Results of bevacizumab as the primary treatment for retinal vein occlusions , 2010, British Journal of Ophthalmology.

[19]  P. Mitchell,et al.  Natural history of branch retinal vein occlusion: an evidence-based systematic review. , 2010, Ophthalmology.

[20]  Sarah Gray,et al.  Ranibizumab for macular edema following central retinal vein occlusion: six-month primary end point results of a phase III study. , 2010, Ophthalmology.

[21]  M. Blumenkranz,et al.  Randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with macular edema due to retinal vein occlusion. , 2010, Ophthalmology.

[22]  P. Campochiaro,et al.  Ranibizumab for macular edema following branch retinal vein occlusion: six-month primary end point results of a phase III study. , 2010, Ophthalmology.

[23]  T. Meigen,et al.  Comparison of Bevacizumab and Triamcinolone for Treatment of Macular Edema Secondary to Branch Retinal Vein Occlusion in a Pair-Matched Analysis , 2010, Ophthalmologica.

[24]  Ingrid U Scott,et al.  A randomized trial comparing the efficacy and safety of intravitreal triamcinolone with observation to treat vision loss associated with macular edema secondary to central retinal vein occlusion: the Standard Care vs Corticosteroid for Retinal Vein Occlusion (SCORE) study report 5. , 2009, Archives of ophthalmology.

[25]  U. Schmidt-Erfurth,et al.  Intravitreal bevacizumab (Avastin®) for macular oedema secondary to retinal vein occlusion: 12-month results of a prospective clinical trial , 2008, British Journal of Ophthalmology.

[26]  R. Avery,et al.  INTRAVITREAL BEVACIZUMAB (AVASTIN) IN THE TREATMENT OF MACULAR EDEMA SECONDARY TO BRANCH RETINAL VEIN OCCLUSION , 2007, Retina.

[27]  J. Simpson,et al.  Intravitreal triamcinolone for refractory diabetic macular edema: two-year results of a double-masked, placebo-controlled, randomized clinical trial. , 2006, Ophthalmology.

[28]  S. Hayreh Prevalent misconceptions about acute retinal vascular occlusive disorders , 2005, Progress in Retinal and Eye Research.